HUMULIN R U-500

Compare HUMULIN R U-500  to:
Compare
Compare

Generic Name for HUMULIN R U-500

Regular insulin (human, recombinant) 500Units/mL; inj; contains m-cresol.

Legal Classification:

Rx

Manufacturer of HUMULIN R U-500

Lilly, Eli and Company

Indications for HUMULIN R U-500

Diabetes.

Adults and Children:

SC injection only. Onset approx 30 minutes, peak 1.75–4hrs, duration up to 24 hrs.

Also:

Warnings/Precautions for HUMULIN R U-500

Instruct patients on diet, exercise, blood or urine testing, proper administration of insulin, change in species of origin, type or purity of insulin, and management of hypoglycemia. Dosage increase may be required during infection, illness, stress, trauma, and pregnancy. Dosage decrease may be needed with renal or hepatic dysfunction.

Interactions for HUMULIN R U-500

Potentiated by salicylates, MAOIs, alcohol, sulfa drugs, some ACE inhibitors, drugs that inhibit pancreatic function (eg, octreotide). Antagonized by corticosteroids, isoniazid, niacin, thiazides, phenothiazines, sympathomimetics. Variable effects with β-blockers, clonidine, lithium salts, alcohol. Onset may be delayed if regular insulin is mixed with zinc insulin. Regular and NPH insulins may be mixed and used immediately or stored for future use.

Adverse Reactions for HUMULIN R U-500

Hypoglycemia, hypokalemia, local or systemic allergy, lipodystrophy, edema.

How is HUMULIN R U-500 supplied?

Vials 70/30, N, R (U-100)—10mL
R (U-500)—20mL
Prefilled disposable Pen (70/30, N)—5x3mL

Related Disease:

Diabetes mellitus~hyperglycemic agents

Related Resources

Finesse insulin patch-pen approved for use with Novolog

July 26, 2010

The FDA has approved Finesse, an insulin patch-pen from Calibra Medical, for up to three-day use with Novolog (insulin aspart, from Novo Nordisk).

Phase 2b study of ARC-4558 for painful diabetic neuropathy (PDN)

July 20, 2010

Arcion Therapeutics announced positive results from a Phase 2b, double-blind, randomized, placebo-controlled clinical trial of ARC-4558 (clonidine HCl 0.1% topical gel) in patients with painful diabetic neuropathy (PDN).

FDA conducts safety review of cancer risk with angiotensin receptor blockers (ARBs)

July 15, 2010

A recently published meta-analysis combining cancer-related findings from several clinical trials is suggesting that angiotensin receptor blockers (ARBs) may be associated with a small increased risk of cancer.

Phase 2b study of INT131 for the treatment of type 2 diabetes

July 01, 2010

InteKrin Therapeutics announced results from its Phase 2b study of INT131 for the treatment of type 2 diabetes.

Phase 1 and 2 studies of antisense therapy for type 2 diabetes

July 01, 2010

Isis Pharmaceuticals announced the presentation of data from its clinical trials of ISIS 113715 and ISIS-GCGRRx for the treatment of diabetes.

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization.

Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions